Last reviewed · How we verify

redness of the eye due to minor eye irritations — Treatment Landscape & Competitive Intelligence

redness of the eye due to minor eye irritations (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating redness of the eye due to minor eye irritations, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
GoodSense Eye Drops Advanced Relief Moisturizer DEXTRAN Allergan Plasma Volume Expander [EPC] 1978-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Allergan · 1 drug in redness of the eye due to minor eye irritations

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in redness of the eye due to minor eye irritations:

Cite this brief

Drug Landscape (2026). redness of the eye due to minor eye irritations — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/redness-of-the-eye-due-to-minor-eye-irritations. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing